Astrazeneca Plc Stock Current Valuation
AZNCF Stock | USD 140.30 1.57 1.13% |
Valuation analysis of AstraZeneca PLC helps investors to measure AstraZeneca PLC's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for AstraZeneca PLC is useful when determining the fair value of the AstraZeneca pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of AstraZeneca PLC. Since AstraZeneca PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AstraZeneca Pink Sheet. However, AstraZeneca PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 140.3 | Real 120.08 | Hype 140.3 |
The real value of AstraZeneca Pink Sheet, also known as its intrinsic value, is the underlying worth of AstraZeneca PLC Company, which is reflected in its stock price. It is based on AstraZeneca PLC's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AstraZeneca PLC helps investors to forecast how AstraZeneca pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: AstraZeneca PLC Company Current Valuation Analysis
AstraZeneca PLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AstraZeneca PLC Current Valuation | 241.1 B |
Most of AstraZeneca PLC's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, AstraZeneca PLC has a Current Valuation of 241.1 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current valuation for all United States stocks is significantly lower than that of the firm.
AstraZeneca Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in current valuation category among related companies.
AstraZeneca Fundamentals
Return On Equity | 0.0863 | |||
Return On Asset | 0.0531 | |||
Profit Margin | 0.07 % | |||
Operating Margin | 0.19 % | |||
Current Valuation | 241.1 B | |||
Shares Outstanding | 1.55 B | |||
Shares Owned By Insiders | 0.22 % | |||
Shares Owned By Institutions | 48.84 % | |||
Price To Earning | 44.18 X | |||
Price To Book | 6.16 X | |||
Price To Sales | 4.73 X | |||
Revenue | 44.35 B | |||
Gross Profit | 35.73 B | |||
EBITDA | 9.33 B | |||
Net Income | 3.29 B | |||
Cash And Equivalents | 4.89 B | |||
Cash Per Share | 3.15 X | |||
Total Debt | 22.96 B | |||
Debt To Equity | 0.87 % | |||
Current Ratio | 0.96 X | |||
Book Value Per Share | 23.91 X | |||
Cash Flow From Operations | 9.81 B | |||
Earnings Per Share | 2.11 X | |||
Price To Earnings To Growth | 1.37 X | |||
Number Of Employees | 42 | |||
Beta | 0.19 | |||
Market Capitalization | 215.86 B | |||
Total Asset | 96.48 B | |||
Retained Earnings | 6.38 B | |||
Working Capital | (2.52 B) | |||
Current Asset | 12.87 B | |||
Current Liabilities | 15.38 B | |||
Z Score | 5.4 | |||
Annual Yield | 0.02 % | |||
Five Year Return | 3.01 % | |||
Net Asset | 96.48 B | |||
Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving against AstraZeneca Pink Sheet
0.49 | UCAR | U Power Limited | PairCorr |
0.45 | NVSEF | Novartis AG | PairCorr |
0.44 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the AstraZeneca PLC information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for AstraZeneca Pink Sheet analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world |